- Home
- KMT vs VRDN Comparison
KMT vs VRDN Comparison
Compare KMT & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KMT | VRDN |
|---|---|---|
| Founded | 1938 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.7B |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | KMT | VRDN |
|---|---|---|
| Price | $40.17 | $29.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | $36.00 | ★ $41.42 |
| AVG Volume (30 Days) | ★ 1.7M | 1.3M |
| Earning Date | 05-06-2026 | 05-25-2026 |
| Dividend Yield | ★ 2.00% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $1,966,845,000.00 | $5,706,000.00 |
| Revenue This Year | $13.94 | $26,080.80 |
| Revenue Next Year | $7.27 | $2.07 |
| P/E Ratio | $54.09 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.30 | $9.90 |
| 52 Week High | $41.74 | $34.29 |
Technical Indicators
Market Signals| Indicator | KMT | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 68.33 | 47.15 |
| Support Level | $37.93 | $21.50 |
| Resistance Level | $41.74 | $33.71 |
| Average True Range (ATR) | 1.36 | 1.41 |
| MACD | -0.20 | 0.04 |
| Stochastic Oscillator | 60.89 | 71.06 |
Price Performance
Historical ComparisonAbout KMT Kennametal Inc.
Kennametal Inc is a manufacturer of metalworking tools and wear-resistant engineered components and coatings. The company operates in two business segments; Metal Cutting and Infrastructure. It generates maximum revenue from the Metal Cutting segment. The Metal Cutting segment develops and manufactures high-performance tooling and metal cutting products and services and offers an assortment of standard and custom metal cutting solutions to diverse end markets, including aerospace, general engineering, energy, and transportation. Geographically, it derives maximum revenue from the United States and the rest from Germany, China, Canada, India, Italy, and other countries.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).